<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628701</url>
  </required_header>
  <id_info>
    <org_study_id>2017/124-31/2</org_study_id>
    <nct_id>NCT05628701</nct_id>
  </id_info>
  <brief_title>Colectomy Reconstruction for Ulcerative Colitis, Ileorectal Anastomosis vs Ileal Pouch-Anal Anastomosis in Ulcerative Colitis.</brief_title>
  <acronym>CRUISE</acronym>
  <official_title>Colectomy Reconstruction for Ulcerative Colitis In Sweden and England: a Multicenter Prospective Comparison Between Ileorectal Anastomosis and Ileal Pouch-Anal Anastomosis After Colectomy in Patients With Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background There are no prospective trials comparing the two main reconstructive options&#xD;
      after colectomy for Ulcerative colitis, ileal pouch anal anastomosis and ileorectal&#xD;
      anastomosis. An attempt on a randomized controlled trial has been made but after receiving&#xD;
      standardized information patients insisted on choosing operation themselves.&#xD;
&#xD;
      Methods Adult Ulcerative colitis patients subjected to colectomy eligible for both ileal&#xD;
      pouch anastomosis and ileorectal anastomosis are asked to participate and after receiving&#xD;
      standardized information the get to choose reconstructive method. Patients not declining&#xD;
      reconstruction or not considered eligible for both methods will be followed as controls. The&#xD;
      CRUISE study is a prospective, non-randomized, multi-center, controlled trial on&#xD;
      satisfaction, QoL, function, and complications between ileal pouch anal anastomosis and&#xD;
      ileorectal anastomosis.&#xD;
&#xD;
      Discussion Reconstruction after colectomy is a morbidity-associated as well as a&#xD;
      resource-intensive activity with the sole purpose of enhancing function, Quality of Life and&#xD;
      patient satisfaction. The aim of this study is to provide the best possible information on&#xD;
      the risks and benefits of each reconstructive treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The CRUISE study is a prospective, non-randomized, non-blinded, multi-center, controlled trial on satisfaction, QoL, function, and complications between IRA and IPAA and permanent stoma among adult UC patients subjected to subtotal colectomy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>2months</time_frame>
    <description>yes/no question if the patient is satisfied with his/her choice of operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1year</time_frame>
    <description>yes/no question if the patient is satisfied with his/her choice of operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>5 years</time_frame>
    <description>yes/no question if the patient is satisfied with his/her choice of operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36(short form-36 item)</measure>
    <time_frame>2 months</time_frame>
    <description>The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36(short form-36 item)</measure>
    <time_frame>6 months</time_frame>
    <description>The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36(short form-36 item)</measure>
    <time_frame>1 year</time_frame>
    <description>The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36(short form-36 item)</measure>
    <time_frame>2 years</time_frame>
    <description>The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36(short form-36 item)</measure>
    <time_frame>5 years</time_frame>
    <description>The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index-6 (FSFI-6)</measure>
    <time_frame>2months</time_frame>
    <description>6 item questionnaire on female sexual function with total score rangeing from 0-34 with lower scores indicating worse sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index-6 (FSFI-6)</measure>
    <time_frame>6months</time_frame>
    <description>6 item questionnaire on female sexual function with total score rangeing from 0-34 with lower scores indicating worse sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index-6 (FSFI-6)</measure>
    <time_frame>1 year</time_frame>
    <description>6 item questionnaire on female sexual function with total score rangeing from 0-34 with lower scores indicating worse sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index-6 (FSFI-6)</measure>
    <time_frame>2 years</time_frame>
    <description>6 item questionnaire on female sexual function with total score rangeing from 0-34 with lower scores indicating worse sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index-6 (FSFI-6)</measure>
    <time_frame>5 years</time_frame>
    <description>6 item questionnaire on female sexual function with total score rangeing from 0-34 with lower scores indicating worse sexual functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function-5 (IIEF-5)</measure>
    <time_frame>2 months</time_frame>
    <description>5 item questionnaire on erectile (dys)function rangeing from 5 to 25 with lower scores indicating worse erectile functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function-5 (IIEF-5)</measure>
    <time_frame>6 months</time_frame>
    <description>5 item questionnaire on erectile (dys)function rangeing from 5 to 25 with lower scores indicating worse erectile functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function-5 (IIEF-5)</measure>
    <time_frame>1 year</time_frame>
    <description>5 item questionnaire on erectile (dys)function rangeing from 5 to 25 with lower scores indicating worse erectile functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function-5 (IIEF-5)</measure>
    <time_frame>2 years</time_frame>
    <description>5 item questionnaire on erectile (dys)function rangeing from 5 to 25 with lower scores indicating worse erectile functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function-5 (IIEF-5)</measure>
    <time_frame>5 years</time_frame>
    <description>5 item questionnaire on erectile (dys)function rangeing from 5 to 25 with lower scores indicating worse erectile functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shor health scale (SHS)</measure>
    <time_frame>2 months</time_frame>
    <description>IDB specific 4 item qualit of life scale rangeing from 0-24 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shor health scale (SHS)</measure>
    <time_frame>6 months</time_frame>
    <description>IDB specific 4 item qualit of life scale rangeing from 0-24 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shor health scale (SHS)</measure>
    <time_frame>1 year</time_frame>
    <description>IDB specific 4 item qualit of life scale rangeing from 0-24 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shor health scale (SHS)</measure>
    <time_frame>2 years</time_frame>
    <description>IDB specific 4 item qualit of life scale rangeing from 0-24 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shor health scale (SHS)</measure>
    <time_frame>5 years</time_frame>
    <description>IDB specific 4 item qualit of life scale rangeing from 0-24 with higher scores indicating worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Öresland Score</measure>
    <time_frame>2 months</time_frame>
    <description>Bowel function score rangeing from 0-17 with higher scores indicating worse functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Öresland Score</measure>
    <time_frame>6 months</time_frame>
    <description>Bowel function score rangeing from 0-17 with higher scores indicating worse functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Öresland Score</measure>
    <time_frame>1 year</time_frame>
    <description>Bowel function score rangeing from 0-17 with higher scores indicating worse functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Öresland Score</measure>
    <time_frame>2 years</time_frame>
    <description>Bowel function score rangeing from 0-17 with higher scores indicating worse functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Öresland Score</measure>
    <time_frame>5 years</time_frame>
    <description>Bowel function score rangeing from 0-17 with higher scores indicating worse functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure</measure>
    <time_frame>2 months</time_frame>
    <description>Extirpation of reconstruction or permanant stoma deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure</measure>
    <time_frame>6 months</time_frame>
    <description>Extirpation of reconstruction or permanant stoma deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure</measure>
    <time_frame>1 year</time_frame>
    <description>Extirpation of reconstruction or permanant stoma deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure</measure>
    <time_frame>2 years</time_frame>
    <description>Extirpation of reconstruction or permanant stoma deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure</measure>
    <time_frame>5 years</time_frame>
    <description>Extirpation of reconstruction or permanant stoma deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reoperations</measure>
    <time_frame>2 months</time_frame>
    <description>number of reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reoperations</measure>
    <time_frame>6 months</time_frame>
    <description>number of reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reoperations</measure>
    <time_frame>1 year</time_frame>
    <description>number of reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reoperations</measure>
    <time_frame>2 years</time_frame>
    <description>number of reoperations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reoperations</measure>
    <time_frame>5 years</time_frame>
    <description>number of reoperations</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Ileostomy - Stoma</condition>
  <arm_group>
    <arm_group_label>IPAA CRUISE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients eligible for both operations choosing ileal pouch anal anastomosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IRA CRUISE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients eligible for both operations choosing ileorectal anastomosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IRA Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients only eligible for ileorectal anastomosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPAA Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients only eligible for ileal pouch anal anastomosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ileostomy Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who decline reconstruction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ileorectal anastomosis (IRA)</intervention_name>
    <description>After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))</description>
    <arm_group_label>IRA CRUISE</arm_group_label>
    <arm_group_label>IRA Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ileal pouch anal anastomosis (IPAA)</intervention_name>
    <description>The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).</description>
    <arm_group_label>IPAA CRUISE</arm_group_label>
    <arm_group_label>IPAA Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ileostomy</intervention_name>
    <description>no reconstruction is performed and the patient is left with his/her ileostomy</description>
    <arm_group_label>Ileostomy Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with Ulcerative colitis (UC) aged between 18 and 60&#xD;
&#xD;
          -  Scheduled for or have previously undergone subtotal colectomy and ileostomy.&#xD;
&#xD;
          -  Patients should have sufficient rectal compliance and controllable inflammation in the&#xD;
             rectal using topical Mezalasin only.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Rectal inflammation of Mayo Score &gt;1&#xD;
&#xD;
          -  Poor sphincter function, perianal disease&#xD;
&#xD;
          -  Uncertainty regarding UC diagnosis P&#xD;
&#xD;
          -  Previous colorectal cancer or severe dysplasia&#xD;
&#xD;
          -  Primary Sclerosing Colitis diagnosis&#xD;
&#xD;
          -  &gt;2 year since subtotal colectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Nordenvall, Ass. Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anton Risto</last_name>
    <phone>0702510374</phone>
    <email>anton.risto@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pär Myrelid, Prof.</last_name>
    <phone>+46 0 10 1031581</phone>
    <email>par.myrelid@liu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska Univercity Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Hermansson</last_name>
      <phone>+46 0 76 0401039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkoeping University hospital</name>
      <address>
        <city>Linköping</city>
        <zip>58731</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Risto</last_name>
      <phone>0702510374</phone>
      <email>anton.risto@liu.se</email>
    </contact>
    <contact_backup>
      <last_name>Pär Myrelid</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <zip>se-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Nordenvall</last_name>
      <phone>+46 0 70 6579109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mark's Hospital</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Deputy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 28, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Anton Risto</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis,</keyword>
  <keyword>Colectomy</keyword>
  <keyword>Reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

